Kivu Bioscience president and COO Mohit Trikha (L) and Novo Holdings partner, venture investments Daniel O’Connell
October 28, 2024 08:00 AM EDTUpdated 09:47 AM
Financing
Startups

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Kyle LaHucik

Senior Reporter

The Dutch biotech Synaf­fix has long been one of the top part­ners for bio­phar­ma com­pa­nies work­ing in an­ti­body-drug con­ju­gates. Now the com­pa­ny is spin­ning out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

For­mer Seagen CEO David Ep­stein to lead new biotech with VEGF bi­func­tion­al an­ti­body

No­var­tis pays Monte Rosa $150M for Phase 1 drug in lat­est en­dorse­ment of mol­e­c­u­lar glues

Fog­Phar­ma re­brands as Para­bilis Med­i­cines, as CEO Math­ai Mam­men high­lights next drugs

Bio­gen's full Ph2 da­ta for IgA nephropa­thy drug; Sanofi in­vests in obe­si­ty biotech

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

A service from the Financial Times